Abstract:The present study highlights the importance of inflammatory response‐related genes in UCEC patients. UCEC patients differ in the expression of IRRGs and could be stratified into different subgroups based on this. Subtype A UCEC patients display better sensitivity to immunotherapy and chemotherapy and, thus, better prognosis. Stratification of patients into different treatment response groups facilitates the formulation of targeted therapy. Furthermore, a novel signature incorporating 12 IRRGs can accurately stratify UCEC patients into high‐ and low‐risk groups and predict the prognosis of these patients. The findings of our study have significant implications for UCEC treatment. Uterine corpus endometrial carcinoma (UCEC) is a prevalent form of cancer in women, affecting the inner lining of the uterus. Inflammation plays a crucial role in the progression and prognosis of cancer, making it important to identify inflammatory response‐related subtypes in UCEC for targeted therapy and personalized medicine. This study discovered significant variation in immune response within UCEC tumors based on molecular subtypes of inflammatory response‐related genes. Subtype A showed a more favorable prognosis and better response to immunotherapies like anti‐CTLA4 and anti‐PDCD1 therapy. Functional analysis revealed subtype‐specific differences in immune response, with subtype A exhibiting higher expression of genes related to cytokine signaling pathways, NK cell‐mediated cytotoxicity pathways and inflammatory processes. Subtype A also showed increased sensitivity to three chemotherapeutic agents. A 12‐gene inflammatory response‐related signature was found to have prognostic value for 1, 2 and 3 year survival in UCEC patients. Additionally, a validated machine learning‐based signature demonstrated significant differences in clinical traits between low‐risk and high‐risk cohorts. Elevated risk scores were associated with higher pathological grading, older age, advanced stage and immune subtype C2. Low‐risk groups had higher infiltration of immune cell types such as CD8 + T cells and activated CD4 + cells. However, the abundance of cytotoxic immune cells decreased with increasing risk scores. Finally, PCR was applied to test the different expression in P2PX4. P2RX4 knockdown inhibited the proliferation and proliferation of the endometrial carcinoma Ishikawa cell line. In conclusion, this developed signature can serve as a clinical prediction index and reveal distinct immune expression patterns. Ultimately, this study has the potential to enhance targeted therapy and personalized medicine for UCEC patients.

Bioinformatics and machine learning-based identification of cell cycle-related genes and molecular subtypes in endometrial cancer

Identification of a 3-Cuproptosis-associated-lncrna-signature That Predicts the Prognosis of Endometrial Cancer Patients

Identification and Validation of a Seven Cuproptosis-Associated Lncrna Signature to Predict the Prognosis of Endometrial Cancer

CDK1 as a Novel Potential Biomarker for Predicting the Prognosis of endometrioid ovarian carcinoma

Combining Bioinformatics and Experiments to Identify and Verify Key Genes with Prognostic Values in Endometrial Carcinoma

Systematic Analysis of the Clinical Relevance of Cell Division Cycle Associated Family in Endometrial Carcinoma

A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients

Identification of Potential Crucial Genes Associated With the Pathogenesis and Prognosis of Endometrial Cancer

Establishment of a novel cell cycle-related prognostic signature predicting prognosis in patients with endometrial cancer

Construction and Validation of an IHC-based Risk Model Predicting Postoperative Disease- Free Survival and Overall Survival in Chinese Endometrial Cancer Patients

Identification of core genes in the progression of endometrial cancer and cancer cell-derived exosomes by an integrative analysis

Integrated Transcriptome and Multiple Activated Pathways in Endometrial Cancer

Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation

Identification of key transcription factors in endometrial cancer by systems bioinformatics analysis

A novel machine learning-based programmed cell death-related clinical diagnostic and prognostic model associated with immune infiltration in endometrial cancer

Regulatory patterns analysis of transcription factor binding site clustered regions and identification of key genes in endometrial cancer

Single-cell analysis reveals landscape of endometrial cancer response to estrogen and identification of early diagnostic markers

Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma

Integrated machine learning identifies a cellular senescence-related prognostic model to improve outcomes in uterine corpus endometrial carcinoma

Identification of Biomarkers for Endometrial Cancer Based on Natural Killer Cell-Related Genes

The inflammatory response‐related robust machine learning signature in endometrial cancer: Based on multi‐cohort studies